Overexpression of the MDM2 Oncogene in Leukemia and Lymphoma

References

• Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Be-Ran M, Cork A, Trujillo J, Gutterman J, Deisseroth A. Rearrangement and expression of p53 in the chronic phase and blastic crisis of chronic myelogeneous leukemia. Blood 1990; 75: 180–189
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F. Mutations of the p53 gene in lymphoid leukemia. Blood 1991; 77: 1153–1156
   PubMed Web of Science ®Google Scholar
• Gaidano G, Ballerini P, Gong J Z, Inghirami G, Neri A, New-Comb E W, Magrath I T, Knowles D M, Dalla-Favera R. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 1991; 88: 5413–5417
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Na-Gai H, Murakami Y, Hayashi K, Saito H. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992; 79: 2701–2707
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81: 3022–3026
   PubMed Web of Science ®Google Scholar
• Baker S J, Fearon E R, Nigro J M, Hamilton S R, Preisinger A C, Jessup J M, van Tuinen P, Ledbetter D H, Barker D F, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217–221
   PubMed Web of Science ®Google Scholar
• Takahashi T, Nau M M, Chiba I, Birrer M J, Rosenberg R K, Vinocour M, Levitt M, Pass H, Gazdar A F, Minna J D. p53: A frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491–494
   PubMed Web of Science ®Google Scholar
• Hollstein M C, Metcalf R A, Welsh J A, Montesano R, Harris C C. Frequent mutation of the p53 gene in human esophageal cancer. Proc. Natl. Acad. Sci. USA 1990; 87: 9958–9961
   PubMedGoogle Scholar
• Lane D P, Crawford L V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261–263
   PubMed Web of Science ®Google Scholar
• Sarnow P, Ho Y S, Williams J, Levine A J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 1982; 28: 387–394
   PubMed Web of Science ®Google Scholar
• Werness B A, Levine A J, Howley P M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 5990; 248: 76–83
   Google Scholar
• Vogelstein B, Kinzler K W. p53 function and dysfunction. Cell 1992; 70: 523–526
   PubMed Web of Science ®Google Scholar
• Hinds P W, Finlay C A, Quartin R S, Baker S J, Fearon E R, Vogelstein B, Levine A J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the “hot spot” mutant pheno-types. Cell. Growth. Differ 1990; 1: 571–580
   PubMedGoogle Scholar
• Momand J, Zambetti G P, Olson D C, George D, Levine A J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245
   PubMed Web of Science ®Google Scholar
• Cahilly-Snyder L, Yang-Feng T, Francke U, George D L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic. Cell. Mol. Genet 1987; 13: 235–244
   PubMedGoogle Scholar
• Fakharzadeh S S, Trusko S P, George D L. Tu-morigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10: 1565–1569
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Cha C, Lewis R, Jhanwar S C, Huvos A G, Healey J H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53: 16–18
   PubMed Web of Science ®Google Scholar
• Oliner J D, Kinzler K W, Meltzer P S, George D L, Vogelstein B. Amplification of a gene encoding a p53-associ-ated protein in human sarcomas. Nature 1992; 358: 80–83
   PubMed Web of Science ®Google Scholar
• Chen J, Marechal V, Levine A J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol 1993; 13: 4107–4114
   PubMed Web of Science ®Google Scholar
• Lovering R, Hanson I M, Borden K L. B, Martin S, O'Reilly N J, Evan G I, Rahman D, Pappin D J. C, Trowsdale J, Freemont P S. Identification and preliminarycharacteriza-tion of a protein motif related to the zinc fmger. Proc. Natl. Acad. Sci. USA 1993; 90: 2112–2116
   PubMed Web of Science ®Google Scholar
• Boddy M N, Freemont P S, Borden K L.B. The p53-associated protein MDM2 contains a newly characterized zinc-binding doman called the RING finger. Trends Biochem. Sci 1994; 19: 198–199
   PubMed Web of Science ®Google Scholar
• Olson D C, Marechal V, Momand J, Chen J, Romocki C, Levine A J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993; 8: 2353–2360
   PubMed Web of Science ®Google Scholar
• Finlay C A. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol 1993; 13: 301–306
   PubMed Web of Science ®Google Scholar
• Oliner J D, Pietenpol J A, Thiagalingam S, Gyuris J, Kinzler K W, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993; 362: 857–860
   PubMed Web of Science ®Google Scholar
• Zauberman A, Barak Y, Ragimov R, Levy N, Oren M. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J 1993; 12: 2799–2808
   PubMed Web of Science ®Google Scholar
• Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461–468
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle J H, Olson D, Levine A J. Genes Dev. The p53-mdm-2 autoregulatory feedback loop 1993; 7: 1126–1132
   Google Scholar
• Juven T, Barak Y, Zauberman A, George D, Oren M. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the MDM2 gene. Oncogene 1993; 8: 3411–3416
   PubMed Web of Science ®Google Scholar
• Zambetti G P, Levine A J. A comparison of the biological activities of wild type and mutant p53. FASEB J 1993; 7: 855–865
   PubMed Web of Science ®Google Scholar
• Perry M E, Piette J, Zawsdzki J A, Harvey D, Levine A J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA 1993; 90: 11623–11627
   PubMed Web of Science ®Google Scholar
• Chen C.-Y, Oliner J D, Zhan Q, Fornace A J, Jr, Vogelstein B, Kastan M B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA 1994; 91: 2684–2688
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Reifenberger J, Ichimura K, Meltzer P S, Collins V P. Amplification and over-expression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736–2739
   PubMed Web of Science ®Google Scholar
• Sheikh M S, Shao Z M, Hussain A, Fontana J A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993; 53: 3226–3228
   PubMed Web of Science ®Google Scholar
• Lianes P, Orlow I, Zhang Z.-F, Oliva M R, Sarkis A S, Reuter V E, Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst 1994; 86: 1325–1330
   PubMed Web of Science ®Google Scholar
• Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu W.-J, Takahashi R, Sugiyama T, Yoshida O. Oncogene amplification in urothelical cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst 1994; 86: 1331–1335
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos C E, Yang Y, de Leon E, McCown P, Stass S A, Albitar M. The human MDM-2 oncogene is over-expressed in leukemias. Blood 1993; 82: 2617–2623
   PubMed Web of Science ®Google Scholar
• Quesnel B, Preudhomme C, Oscier D, Lepelley P, Collyn-d'Hooghe M, Falcon T, Zandecki M, Fenaux P. Over-expression of the MDM2 gene in found in some cases of hematological malignancies. Br. J. Haematol 1994; 88: 415–418
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Quesnel B, Vachee A, Lepelley P, Collyn-D'Hooghe M, Wattel E, Fenaux P. Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia 1993; 7: 1291–1293
   PubMed Web of Science ®Google Scholar
• Ridge S A, Dyer M, Greaves M F, Wiedemann L M. Lack of MDM2 amplification in human leukemia. Br. J. Haematol 1994; 86: 407–409
   PubMed Web of Science ®Google Scholar
• Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158–3165
   PubMed Web of Science ®Google Scholar
• Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, Barbareschi M, Scarpa A, Mariuzzi G M, Pizzolo G. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 1994; 84: 4295–4300
   PubMed Web of Science ®Google Scholar
• Mosner J, Deppert W. p53 and mdm2 are expressed independently during cellular proliferation. Oncogene 1994; 9: 3321–3328
   PubMed Web of Science ®Google Scholar
• Huang Y Q, Raphael B, Buchbinder A, Li J J, Zhang W G, Friedman-Kien A E. Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia. Am. J. Hematol 1994; 47: 139–141
   PubMed Web of Science ®Google Scholar
• Milner J, Medcalf E A. Cotranslation of activated mutant p53 with wild type drives the wild-type 53 protain into the mutant conformation. Cell 1991; 65: 765–774
   PubMed Web of Science ®Google Scholar
• Flørens V A, Melandsmo G M, Forus A R, Andreassen A, Myklebost O, Fodstad O S. MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53 gene status. J. Natl. Cancer Inst 1994; 86: 1297–1302
   PubMed Web of Science ®Google Scholar
• Zhang W, Shay J W, Deisseroth A. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. Cancer Res 1993; 53: 4772–4775
   PubMed Web of Science ®Google Scholar
• Marechal V, Elenbaas B, Piette J, Nicols J.-C, Levine A J. The ribosomal L5 prtein is associated with mdm-2 and mdm2-p53 comlexes. Mol. Cell. Biol 1994; 14: 7414–7420
   PubMed Web of Science ®Google Scholar
• Landers J E, Haines D S, Strauss I II J. F., George D L. Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994; 9: 2745–2750
   PubMed Web of Science ®Google Scholar
• Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307–3180
   PubMed Web of Science ®Google Scholar